Internal Medicine, Infectious Disease · Hackensack, NJ
NPI
1730103789
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
20 Prospect Ave, Suite 507
Hackensack, NJ, 07601
Phone (201) 487-4088
Groups this clinician bills Medicare through
Medicare paid, 2024
$160K
1,838 services
Medicare patients, 2024
408
Average age 74
Drug cost, 2024
$2.1M
774 prescriptions
Company payments, 2025
$130
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Samit Desai was code 99232 (hospital e&m - subsequent), 934 times for 266 patients. In total Samit Desai billed 1,838 services in 23 codes, and Medicare paid $160K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-08-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 934 | 266 | $69.54 | $65K |
| 99233 Hospital E&M - Subsequent | Facility | 345 | 114 | $105.18 | $36K |
| 99222 Hospital E&M - Initial | Facility | 212 | 189 | $111.20 | $24K |
| 99223 Hospital E&M - Initial | Facility | 131 | 120 | $152.50 | $20K |
| 99231 Hospital E&M - Subsequent | Facility | 91 | 81 | $43.54 | $3,962 |
| 99213 Office E&M - Established | Office | 48 | 40 | $68.84 | $3,304 |
| 99214 Office E&M - Established | Office | 22 | 17 | $102.97 | $2,265 |
By year: 2022 $146K for 1,839 services; 2023 $142K for 1,743 services; 2024 $160K for 1,838 services.
Medicare prescription drug claims, 2024
In 2024, the drug Samit Desai prescribed most often to Medicare patients was Odefsey (Emtricitab/Rilpiviri/Tenof Ala), with 73 prescriptions and refills. In total Samit Desai wrote 774 Medicare prescriptions that cost $2.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Odefsey Emtricitab/Rilpiviri/Tenof Ala | 73 | 77 | Under 11 | $292K |
| Dovato Dolutegravir Sodium/Lamivudine | 61 | 63 | Under 11 | $182K |
| Juluca Dolutegravir/Rilpivirine | 61 | 61 | Under 11 | $219K |
| Rukobia Fostemsavir Tromethamine | 49 | 49 | Under 11 | $457K |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 48 | 48 | Under 11 | $206K |
| Tivicay Dolutegravir Sodium | 43 | 43 | Under 11 | $157K |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | 36 | 36 | Under 11 | $158K |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 30 | 30 | Under 11 | $117K |
| Pifeltro Doravirine | 27 | 29 | Under 11 | $52K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 22 | 44 | 13 | $338 |
| Daptomycin Generic | 21 | 21 | Under 11 | $32K |
| Delstrigo Doravirine/Lamivu/Tenofov Diso | 21 | 21 | Under 11 | $59K |
| Ceftriaxone Ceftriaxone Sodium | 19 | 19 | Under 11 | $2,880 |
| Descovy Emtricitabine/Tenofov Alafenam | 16 | 16 | Under 11 | $21K |
| Valacyclovir Valacyclovir Hcl | 15 | 17 | Under 11 | $216 |
Brand drugs: 496 claims; generic drugs: 278 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Samit Desai $130 ($130 in general payments such as food, travel and fees) from 3 companies. The largest payer was Abbvie Inc. with $95.26.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.